SCM
ANTX icon

Stonepine Capital Management’s AN2 Therapeutics ANTX Stock Holding History

Stonepine Capital Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.67M Sell
551,692
-162,153
-23% -$697K 1.51% 24
2026
Q1 		$2.44M Buy
713,845
+86,177
+14% +$178K 0.98% 16
2025
Q4 		$716K Buy
627,668
+63,755
+11% +$74.5K 0.52% 44
2025
Q3 		$716K Buy
563,913
+19,419
+4% +$22.2K 0.58% 33
2025
Q2 		$577K Buy
+544,494
New +$649K 0.57% 39
2025
Q1 		– Sell
-196,732
Closed -$271K – 69
2024
Q4 		$271K Buy
+196,732
New +$239K 0.22% 45

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Stonepine Capital Management's ANTX Position: Q2 2026 in Review

Stonepine Capital Management reduced its AN2 Therapeutics (ANTX) stake by 23% in Q2 2026, selling an estimated $697K and leaving 551,692 shares worth $2.67M. The position accounts for 1.51% of the portfolio, ranked #24.

Stonepine Capital Management first reported a position in ANTX in Q4 2024 and has held it in 6 quarters since. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Stonepine Capital Management held 551,692 shares of AN2 Therapeutics worth $2.67M as of Q2 2026.
  • Stonepine Capital Management sold 162,153 AN2 Therapeutics shares in Q2 2026, an estimated $697K.
  • AN2 Therapeutics made up 1.51% of Stonepine Capital Management's portfolio in Q2 2026, its #24 holding.
  • Stonepine Capital Management first reported a position in AN2 Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.